Архів
|
ЛІТЕРАТУРА
- McLeod, D.C.,
“An analgesic for non-prescription pain reliever promotions”,
Drug Intelligence and Clinical Pharmacy, Vol 22, Jun 1988, p503.
- Grichnik, K.P.
and Ferrante, P.M., “The difference between acute and chronic pain”,
Mount Sinai Journal of Medicine, Vol 58, No 3, May 1991, pp217-20.
- Holland, A.J.A.,
Jackson, S.H.D. and Turner, P., “A survey of analgesic drug utilization
within and between clinical units in a health district”, International
Journal of Clinical Pharmacology, Therapy and Toxicology, Vol 26,
No 9, 1988, pp465-7.
- Greenwald,
H.P., “Interethnic differences in pain perception”, Pain,
Vol 44, 1991, pp157-63.
- Po, A.L.W.,
Non-Prescription Drugs, Oxford, Blackwell Scientific, (2nd edn)
1990, p9.
- According to
a 1989 report, Accelerated Growth in Pain Management Markets: Forecasts
of Pharmaceuticals, Devices and Alternative Treatments, by the Market
Intelligence Research Company, reported in: Anon., “New Publications”,
Scrip, No 1483, 26 Jan 1990, p4.
- According to
a 1991 Frost and Sullivan report, The European Market for Pain Management
Products — Pharmaceutical: Pain Control Devices & Alternative
Medicines, reported in: Anon., “European pain relief market set to
rise”, Scrip, No 1587, 1 Feb 1991, p27.
- Laurence, D.R.
and Bennett, P.N., Clinical Pharmacology, Edinburg, Churhill
Livingstone, (6th edn), 1987, p301.
- Ibid, p302.
- Acs, G. and
Drazner, E., “The incidence of postoperative pain and analgesic usage
in children”, Journal of Dentistry for Children, Jan-Feb 1992,
pp48-52.
- Liebeskind,
J.C., “Pain can kill”. Pain, Vol 44, 1991, pp3-4.
- Grichnik and
Ferrante, op cit, pp217-20.
- Laurence and
Bennett, op cit, p303.
- Gaukroger,
P.В., “Paediatric analgesia: Which drug? Which dose?”, Drugs,
Vol 41, No 1, 1991, pp52-9.
- Maunuksela,
E-L. and Oikkola, K.T., “Pediatnc pain management” International
Anesthesiology Clinics, Vol 29, No 2, May 1991, pp37-55 (However,
pain resulting from chronic diseases or surgery does demand sensitive
and often prophylactic therapy as children typically do not request
analgesics as adults do.).
- Grichnik and
Ferrante, op cit, pp217-20.
- Lebovits,
A.H., “Chronic pain: the multidisciplinary approach”, International
Anesthesiology Clinics, Vol 29, No 1, 1991, pp1-7.
- Ibid; Turk,
D.C. and Rudy, Т.Е., “Neglected topics in the treatment of chronic
pain patients — relapse, non-compliance, and adherence enhancement”,
Pain, Vol 44, 1991, pp5-28.
- Parish, P.,
Medicines: A Guide for Everybody, (6th edn, revised), London, Penguin,
1989, p187.
- Katz, J. and
Melzack, R., “Auricular transcutaneous electrical nerve stimulation
(TENS) reduces phantom limb pain”, Journal of Pain and Symptom
Management, Vol 6, No 2, Feb 1991, pp73-83.
- Beecher, H.K.,
“The powerful placebo”, Journal of the American Medical Association,
Vol 159, 1955, pp1602-6.
- Scarani, G.,
Beghi, E. and Tognoni, G., “Pharmacological treatment of a primary
headache: analysis of current practice from a drug utilization study”,
Headache, Vol 27, Jun 1987, pp345-50.
- Laurence and
Bennett, op cit, p307.
- Henry, J.(ed.),
The British Medical Association Guide to Medicines & Drugs,
London, Dorling Kindersley (2nd edn) 1991, p77.
- Parish, op
cit, p188.
- Wall, P.D.
and Melzack R., (eds), Textbook of Pain, London, Churchill Livingstone,
1984, p505.
- Gilman, A.G.,
Rail, T.W., Nies, A.S., and Taylor, P. (eds), Goodman and Gilman's
The Pharmacological Basis of Therapeutics, New York, Pergamon Press,
(8th edn) 1990, p638.
- WHO, “WHO
Model List: revised in November 1991”, WHO Drug Information,
Vol 5, No 4, 1991, p182.
- Chetley, A.
and Gilbert, D., Problem Drugs, The Hague/Penang, Health Action
International, 1986.
- Hartog, R.
and Schulte-Sasse, H., German and Swiss drug supplies to the Third
World, Amsterdam/Zurich/Lausanne/Bielefeld, HAI-Europe/Berne Declaration
Group/ BUKO Pharma-Kampagne, 1990, p32.
- Gillies, H.C.,
Rogers, H.J., Spector, R.G. and Trounce, J.R., A Textbook of
Clinical Pharmacology, (2nd edn), London, Hodder and Stoughton,
1986, p308.
- AMA, Drug
Evaluations, Philadelphia, W.B. Saunders Co., (6th edn) 1986, p76.
- Henry, op
cit, p77.
- BMA and the
Royal Pharmaceutical Society of Great Britain, British National Formulary,
London, BMA and The Pharmaceutical Press, No 22, Sep 1991, p161.
- Analgesic
Guidelines Sub-Committee, Victorian Drug Usage Advisory Committee, Analgesic
Guidelines, (1s1 edn), Toorak, Victorian Medical Postgraduate Foundation,
1988, p22.
- Anon., “New
Swiss analgesic prescribing rules”, Scrip, No 1607, 12 Apr
1991, p9.
- Analgesic
Guidelines Sub-Committee, op cit, p192.
- Parish, op
cit, p192.
- BMA and the
Royal Pharmaceutical Society of Great Britain, op cit, p18.
- Ibid, p161.
- Laurence and
Bennett, op cit, p307.
- Po, op cit,
p535.
- Gilman, et
al, p629.
- Schachtel,
B.P., Fillingim, J.M., et al, “Caffeine as an analgetic adjuvant:
a doubleblind study comparing aspirin with caffeine to aspirin and placebo
in patients with sore throat”, Archives of Internal Medicine,
Vol 151, Apr 1991, pp733-7.
- Ward, N.,
Whitney, C., Avery, D. and Dunner, D., “The analgesic effects of caffeine
in headache”, Pain, Vol 44, 1991, pp151-5.
- Forbes, J.A.,
Jones, K.F., et al, “Evaluation of aspirin, caffeine, and their combination
in postoperative oral surgery pain”, Pharmacotherapy, Vol 10,
No 6, 1990, pp387-93.
- Bennett, W.M.
and DeBroe, M.E. “Analgesic nephropathy — a preventable disease”,
New England Journal of Medicine, Vol 320, No 19, 11 May 1989, pp1269-71.
- Hoskin, P.J.
an Hanks, G.W., “Opioid agonist-antagonist drugs in acute and chronic
pain states”, Drugs, Vol 41, No 3, 1991, pp326-44.
- BMA and the
Royal Pharmaceutical Society of Great Britain, op cit, p132.
- United Nations,
Consolidated List of Products Whose Consumption and/or Sale Have Been
Banned, Withdrawn, Severely Restricted or Not Approved by Governments,
2nd issue, Doc No ST/ESA/192, New York, 1987, pp105, 107, 118.
- BMA and the
Royal Pharmaceutical Society of Great Britain, p159.
- Wall and Melzack,
op cit, p507.
- Jones, M.P.
and Schubert, M.L., “What do you recommend for prophylaxis in an elderly
woman with arthritis requiring NSAIDs for control?”, American Journal
of Gastroenterology, Vol 86, No 3, 1991,
pp264-6.
- Graedon,J.
and Graedon, Т., Graedon’s Best Medicine: from herbal remedies
to high-tech Rx breakthrough, New York, Bantam Books, 1991, p79.
- BMA and the
Royal Pharmaceutical Society of Great Britain, op cit, p159.
- Lesser, F.,
“Aspirin: the slow gestation of a warning”, New Scientist,
19 Jun 1986, p23.
- Lopez, R.
and Kroeger, A. (eds), Morbilidad
у Medicamentos en Peru у Bolivia, Lima/ Heidelberg/Chimbote, Universidad
Peruana Cayetano Heredia/Universidad de Heidelberg/Accion para la Salud,
1990, p146.
- MaLAM letter
to Nicholas, March 1990.
- Wall and Melzack
(eds), op cit, p507.
- BMA and the
Royal Pharmaceutical Society of Great Britain, op cit, p159.
- Parish, op
cit, p195.
- Nelson, S.D.,
“Molecular mechanisms of the hepatotoxicity caused by acetaminophen”,
Seminars in Liver Disease, Vol 10, No 4, 1990, pp267-78.
- Levy, M.,
“Adverse reactions to over-the-counter analgesics: an epidemiological
evaluation”, Agents Actions Supplement, Vol 25, 1988, pp21-31.
- Diamond, J.,
“They'll never swallow that”, Sunday Times Magazine, 17 May
1987, pp824.
- BMA and the
Royal Pharmaceutical Society of Great Britain, op cit, p18.
- Sandier, D.P.
and Weinberg, C.R., “Analgesic use and chronic renal disease”,
New England Journal of Medicine, Vol 321, No 16, 19 Oct 1989, pp1126-7.
- Burk, R.F.,
“N-acetylcysteine in the treatment of acetaminophen overdose”,
New England Journal of Medicine, Vol 320, No 21, 25 May 1989, p1418.
- AMA, op cit,
p75.
- Gilman, et
al, op cit, pp665-6.
- Physicians'
Desk Reference, Oradell, N.J., Medical Economics Company, 44th edn,
1990, p2293.
- Anon., “Junifen
suspension-ibuprofen for febrile children”, Drug and Therapeutics
Bulletin, Vol 29, No 3, 4 Feb 1991, pp11-12.
- Reynolds,
J.E.F. (ed.), Martindale: The Extra Pharmacopoeia, London, The
Pharmaceutical Press, (29th edn) 1989, p1321.
- Anon., “Grunenthal
pursues tramadol”, Scrip, No 1509, 27 Apr 1990, p34.
- Offerhaus,
L., “Glafenine: Kiespijn of kiespijn?” (Glafenine: toothache or
toothache?), Nederlands Tijdschr Geneeskd, Vol 132, No 40, 1988,
pp1853-57.
- Anon., “Glafenine
withdrawn in Belgium”, Scrip, No 1581, 11 Jan 1991, p34. In
1991, glafenine was marketed in 78 countries, according to an article
in The Lancet (Vol 339, 8 Feb 1992, p357).
- Offerhaus,
op cit, pp1853-57.
- Dukes, M.N.G.
and Beeley, L. (eds), Side Effects of Drugs Annual 12, Amsterdam, Elsevier,
1988, p90.
- Offerhaus,
op cit, pp1853-57.
- Stricker B.H.Ch.,
de Groot, R.R.M. and Wilson, J.H.P., “Anaphylaxis to glafenine”,
Lancet, Vol 336, No 8720, 13 Oct 1990, pp943-4.
- Herxheimer,
A., “Belgium: Withdrawal of glafenine”, Lancet, Vol 337,
No 8733, 12 January 1191, p102.
- BUKO Pharma-Kampegne,
Hoechst: A Cause of Illness?, Bielefeld, BUKO Pharma-Kampange, 1987,
pp21-2
- MaLAM letter
to Roussel, June 1990.
- Anon.,
Scrip, No 1581, op cit, p34.
- Anon., “Glafenine
withdrawal recommended”, Scrip, No 1685, 22 Jan 1992, p23.
- Anon., “Withdrawal
of glafenine”, Lancet, Vol 339, No 8789, 8 Feb 1992, p357.
- Anon., “Glafenine:
voluntary withdrawal”, WHO Drug Information, Vol 6, No 2, 1992,
p57.
- Sanberg, P.
and Krema, R.M.T., Over-the-counter Drugs: harmless or hazardous?,
London, Burke Publishing, 1988, p49.
- Dubach, U.C.,
Rosner, B. and Stunner, Т., “An epidemiological study of abuse of
analgesic drugs: effects of phenacetin and salicylate on mortality and
cardiovascular morbidity (1968 to 1987)”, New England Journal of
Medicine, Vol 320, No 19,11 May 1989, pp155-60.
- Sandier, D.P.,
Smith, J.C., et al, “Analgesic use and chronic renal disease”,
New England Journal of Medicine, Vol 320, No 19, 11 May 1989, pp1238-43.
- Stolley, P.D.,
“The risks of phenacetin use”, New England Journal of Medicine,
Vol 324, No 3, 17 Jan 1991, pp191-3.
- Graedon.J.,
The People's Pharmacy-2, New York, Avon Books, 1980, p41.
- United Nations,
op cit, p77.
- Ibid, pp76-8;
Anon., “FRG voluntary phenacetin withrawals”, Scrip, No 1081,
3 Mar 1986, p3; Consumers' Association of Penang, Drugs and the Third
World: Phenacetin risks, benefits and marketing in Malaysia, Penang,
CAP, 1986, p4.
- Gilman, et
all, op cit, pp654-5.
- Anon., “Hoechst
in 1987 and 1988”, Scrip, 23 Mar 1988, p14.
- Anon., “Good
growth for Hoechst Pharma”, Scrip, No 1702, 20 Mar 1992, pp8-9.
- Reynolds,
op cit, p15.
- Laurence and
Bennett, op cit, p168.
- Fuellgraff,
G. and Palm, D. (eds), Pharmakotherapie
— Klinische Pharmakologie, (6th edn), Stuttgart, Gustav Fischer
Verlag, 1986, p194.
- AMA, Drug
Evaluations, (2nd edn), Chicago, 1973, pp262-7.
- AMA Drug
Evaluations, (3rd edn), Chicago, 1977, p341.
- United Nations,
op cit, p62.
- United Nations,
op cit, p115.
- United Nations,
op cit, pp62-3.
- United Nations,
op cit, p89.
- United Nations,
op cit, p90.
- Bennett and
DeBroe, op cit, pp.1269-71.
Назад
|
|